Rivaroxaban beats Lovenox: RECORD4 trial

15 June 2008

Results from a pivotal Phase III trial presented at the annual meeting of the European Federation of National Associations of Orthopedics & Traumatology, in Nice, France, demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior to enoxaparin in preventing venous blood clots in patients who underwent total knee replacement surgery.

The head-to-head study compared the agent with the US-approved dosing regimen for Sanofi-Aventis' Lovenox (enoxaparin), the current standard-of-care. Rivaroxaban is being jointly developed by US health care major Johnson & Johnson and Germany's Bayer HealthCare.

The RECORD4 data show that rivaroxaban (10mg once-daily) provided TKR surgery patients a statistically-significant 31% relative risk reduction in total venous thromboembolism events - defined in the study as the composite of all deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality - compared to enoxaparin (30mg twice-daily; 6.9% and 10.1%, respectively, p=0.012). Rates of major bleeding, the main safety endpoint, were greater in rivaroxaban-treated patients. This difference was not statistically significant from the rate of major bleeding in enoxaparin-treated patients (p=0.110).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight